News and Trends 26 Feb 2019
Immuno-oncology Biotech Raises €31M to Progress T-Cell Boosting Therapy
The Swiss biotech Anaveon closed a very respectable €31M (CHF35M) Series A fundraising round to help progress its T-cell boosting, cancer-fighting treatment to the clinic. The company’s candidate therapy mimics the action of a protein called interleukin 2, which is naturally found in the body. Interleukin 2 stimulates the immune system to produce more infection-fighting […]